학술논문
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
Document Type
article
Author
Keigo Chida; Daisuke Kotani; Toshikazu Moriwaki; Shota Fukuoka; Toshiki Masuishi; Atsuo Takashima; Yosuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Masato Komoda; Akitaka Makiyama; Tadamichi Denda; Yukimasa Hatachi; Takeshi Suto; Naotoshi Sugimoto; Masanobu Enomoto; Toshiaki Ishikawa; Tomomi Kashiwada; Koji Ando; Satoshi Yuki; Yoshihiro Okita; Hitoshi Kusaba; Daisuke Sakai; Koichi Okamoto; Takao Tamura; Kimihiro Yamashita; Masahiko Gosho; Yasuhiro Shimada
Source
Frontiers in Oncology, Vol 11 (2021)
Subject
Language
English
ISSN
2234-943X
Abstract
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.Patients and Methods: We analyzed patients registered in the REGOTAS study, which retrospectively compared the efficacy and safety of use of REG or TFTD as later-line chemotherapy for chemorefractory mCRC patients. We compared the survival outcomes of cohort A (treated using both REG and TFTD) and cohort B (treated using either REG or TFTD).Results: A total of 550 patients (cohort A, n = 252; cohort B, n = 298) met the inclusion criteria. The median OS was significantly increased in cohort A compared with cohort B [9.6 months (95% confidence interval (CI), 8.9–10.9 months) vs. 5.2 months (95% CI, 4.4–6.0 months), P < 0.001]. Multivariate analysis revealed that cohort A was independently associated with a significant increase in OS [A vs. B: Hazard ratios (HR), 0.58; 95% CI, 0.47–0.72; P < 0.001]. Subgroup analysis adjusted using multivariate Cox model revealed a consistently better trend in most subgroups for cohort A compared with cohort B.Conclusions: Our study revealed prolonged survival in patients treated with REG and TFTD. Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients.